[go: up one dir, main page]

DK1201639T3 - Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser - Google Patents

Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser

Info

Publication number
DK1201639T3
DK1201639T3 DK02001564T DK02001564T DK1201639T3 DK 1201639 T3 DK1201639 T3 DK 1201639T3 DK 02001564 T DK02001564 T DK 02001564T DK 02001564 T DK02001564 T DK 02001564T DK 1201639 T3 DK1201639 T3 DK 1201639T3
Authority
DK
Denmark
Prior art keywords
treatment
cell proliferative
proliferative disorders
lipoxin compounds
compounds
Prior art date
Application number
DK02001564T
Other languages
Danish (da)
English (en)
Inventor
Charles N Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK1201639T3 publication Critical patent/DK1201639T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK02001564T 1996-09-13 1997-09-15 Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser DK1201639T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/712,610 US6048897A (en) 1993-06-15 1996-09-13 Lipoxin compounds and their use in treating cell proliferative disorders
PCT/US1997/016342 WO1998011049A1 (fr) 1996-09-13 1997-09-15 Composes de lipoxines et leur utilisation dans le traitement des pathologies dues a la proliferation cellulaire

Publications (1)

Publication Number Publication Date
DK1201639T3 true DK1201639T3 (da) 2008-11-24

Family

ID=24862848

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97941078T DK0927150T3 (da) 1996-09-13 1997-09-15 Lipoxinforbindelser og deres anvendelse til behandling af celleformeringsforstyrrelser
DK02001564T DK1201639T3 (da) 1996-09-13 1997-09-15 Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK97941078T DK0927150T3 (da) 1996-09-13 1997-09-15 Lipoxinforbindelser og deres anvendelse til behandling af celleformeringsforstyrrelser

Country Status (11)

Country Link
US (9) US6048897A (fr)
EP (3) EP0927150B1 (fr)
JP (1) JP4060366B2 (fr)
AT (2) ATE404522T1 (fr)
AU (1) AU723321B2 (fr)
CA (1) CA2265708C (fr)
DE (2) DE69738918D1 (fr)
DK (2) DK0927150T3 (fr)
ES (2) ES2312499T3 (fr)
PT (2) PT1201639E (fr)
WO (1) WO1998011049A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
WO2000002851A1 (fr) * 1998-07-08 2000-01-20 Aventis Pharma Deutschland Gmbh N-arylamides d'acide sulfonylaminocarboxylique a substitution soufre, preparation et utilisation de ces derniers, preparations pharmaceutiques contenant ces composes
EP1616566A1 (fr) * 1999-03-18 2006-01-18 The Brigham And Women's Hospital, Inc. Composés de lipoxin pour traiter des inflammations induite par TNF-alpha
WO2000054767A1 (fr) 1999-03-18 2000-09-21 Brigham And Women's Hospital UTILISATION DE COMPOSES DE LIPOXINE AFIN D'INHIBER LA REPONSE DE NEUTROPHILE INDUITE PAR TNF$g(a)
ES2246230T3 (es) * 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
EP1586550A1 (fr) * 1999-03-18 2005-10-19 The Brigham And Women's Hospital, Inc. Composés à base de lipoxine et leur utilisation
AU2004235617B2 (en) * 1999-03-18 2008-06-05 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
TR200201244T2 (tr) 1999-11-09 2002-08-21 Alcon, Inc. Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları
IL151299A0 (en) * 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AU2001249329A1 (en) * 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
JP2005508282A (ja) * 2001-03-02 2005-03-31 ザ・ブリガム・アンド・ウイメンズ・ホスピタル 新規な脈管形成抑制剤としてのリポキシン類似物
ES2344814T3 (es) * 2001-03-02 2010-09-07 The Brigham And Women's Hospital Analogos de lipoxina como nuevos inhibidores de la angiogenesis.
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
EP1911448B1 (fr) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Lipoxines, lipoxines déclenchées par l'aspirine et leurs analogues stables dans le traitement de l'asthme et maladies inflammatoires de voies respiratoires
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
WO2003039533A1 (fr) 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxines et lipoxines activees par aspirine et leurs analogues stables dans le traitement de l'asthme et de maladies respiratoires inflammatoires
EP1941875B1 (fr) * 2001-12-18 2012-09-12 The Brigham and Women's Hospital Utilisation d'analogue de la lipoxine pour améliorer la défense cellulaire contre les infections gram-négatives
WO2003053423A2 (fr) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Nouvelle methode de defense antimicrobienne de l'hote utilisant des boucliers moleculaires comportant des analogues de rra et de dha
WO2003051350A1 (fr) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Utilisation d'analogues de lipoxine pour activer la defense cellulaire contre des infections gram negatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DK2216318T3 (en) 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
WO2004078143A2 (fr) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Procede destine a l'identification et l'utilisation de recepteurs anti-inflammatoires pour les analogues d'acides eicosapentaenoiques
GB0313259D0 (en) * 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
EP1755537A4 (fr) * 2004-04-14 2009-12-09 Univ Boston Procédés et compositions servant à prévenir ou à traiter des maladies parodontales
ATE461696T1 (de) * 2004-11-09 2010-04-15 Alcon Inc 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8245230B2 (en) * 2005-03-14 2012-08-14 Qnx Software Systems Limited Adaptive partitioning scheduler for multiprocessing system
WO2007041440A2 (fr) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Effets anti-inflammatoires de la neuroprotectine d1/protectine d1 et de ses stereoisomeres naturels
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
CA2650607A1 (fr) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions et procedes destines au traitement d'une maladie cardiovasculaire
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
JP2009026126A (ja) * 2007-07-20 2009-02-05 Nec Electronics Corp 半導体装置
CN101843622B (zh) * 2010-04-27 2011-09-14 黄波 脂氧素在制备女性避孕药物中的应用
US9439966B2 (en) 2011-10-12 2016-09-13 Case Western Reserve University Multi-component nanochains
EP2917738A1 (fr) 2012-11-12 2015-09-16 BIOCRATES Life Sciences AG Utilisation d'indicateurs de qualité pour la mise en évidence de processus de décongélation d'échantillons de tissus congelés
CN105439813B (zh) * 2014-08-08 2017-10-27 广州丹康医药生物有限公司 化合物的合成方法
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
US11592453B2 (en) 2016-11-22 2023-02-28 The Brigham And Women's Hospital, Inc. Personalized metabolomic profiling of specialized pro-resolving mediators
CA3055093A1 (fr) 2017-03-09 2018-09-13 University Health Network Neuroprotection mediee par la lipoxine et un analogue de la lipoxine et traitements
EP3911336A4 (fr) 2019-01-18 2023-05-10 Case Western Reserve University Composés ciblés sur le ligand du psma et leurs utilisations
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
KR20240150603A (ko) 2022-03-03 2024-10-15 테티스 파마수티컬스 엘엘씨 특수화된 해소촉진 매개체의 시클로덱스트린 복합체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560514A (en) * 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4780281A (en) 1985-06-14 1988-10-25 Wayne State University Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja) 1986-02-26 1987-09-02 Nissan Chem Ind Ltd テトラオ−ル誘導体
JPH0739368B2 (ja) 1986-10-01 1995-05-01 旭硝子株式会社 ２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (fr) * 1987-07-08 1994-05-24 Nissan Chemical Industries, Ltd. Alcool allylque optiquement actif et procede pour la production de leucotriene b_ et son utilisation
JPH01228994A (ja) 1988-03-10 1989-09-12 Fumie Satou γ−シリルアリルアルコール及びその製造法
US5079261A (en) * 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja) 1990-01-30 1998-12-09 帝人株式会社 リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en) 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja) 1993-01-20 2001-11-12 富士電機株式会社 自動販売機
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO1994029262A1 (fr) * 1993-06-15 1994-12-22 Brigham & Women's Hospital Composes de la lipoxine
US6048897A (en) * 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
WO1995001179A1 (fr) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation d'inflammation liees a l'epithelium cylindrique
US5998487A (en) 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
US6486203B1 (en) 1998-09-08 2002-11-26 Cornell Research Foundation, Inc. Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease

Also Published As

Publication number Publication date
DE69711894D1 (de) 2002-05-16
AU4271097A (en) 1998-04-02
ATE404522T1 (de) 2008-08-15
JP2001500866A (ja) 2001-01-23
DK0927150T3 (da) 2002-07-22
EP1201639B1 (fr) 2008-08-13
US6316648B1 (en) 2001-11-13
ES2175460T3 (es) 2002-11-16
PT1201639E (pt) 2008-10-03
EP0927150B1 (fr) 2002-04-10
AU723321B2 (en) 2000-08-24
DE69738918D1 (de) 2008-09-25
JP4060366B2 (ja) 2008-03-12
ATE215924T1 (de) 2002-04-15
EP1201639A2 (fr) 2002-05-02
CA2265708A1 (fr) 1998-03-19
CA2265708C (fr) 2003-06-10
PT927150E (pt) 2002-08-30
EP2058293A1 (fr) 2009-05-13
WO1998011049A1 (fr) 1998-03-19
US6653493B2 (en) 2003-11-25
US20030032827A1 (en) 2003-02-13
US6620919B2 (en) 2003-09-16
US20020111505A1 (en) 2002-08-15
EP0927150A1 (fr) 1999-07-07
US20020091279A1 (en) 2002-07-11
US20030134901A1 (en) 2003-07-17
US6635776B2 (en) 2003-10-21
DE69711894T2 (de) 2002-11-14
US6750360B2 (en) 2004-06-15
US20020082435A1 (en) 2002-06-27
EP1201639A3 (fr) 2003-01-02
US20010031882A1 (en) 2001-10-18
US6048897A (en) 2000-04-11
ES2312499T3 (es) 2009-03-01
US20020010351A1 (en) 2002-01-24
US6569075B2 (en) 2003-05-27

Similar Documents

Publication Publication Date Title
DK1201639T3 (da) Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
DE69434218D1 (de) Photodynamische behandlung von synovium
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
MY121548A (en) Compounds and methods for the treatment of cancer
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE69708121D1 (de) Halogenid-enthaltende insulinzubereitungen
DK0703897T3 (da) Lipoxinforbindelser med forlænget halveringstid
DE69814394D1 (de) Verwendung von levobupivacain
DE69133022D1 (de) Viral verursachte Zerstörung von Neoplastzellen
DK1702618T3 (da) Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DK0971710T3 (da) Anvendelse af chelerythrin og stråling til tumorterapi
BG101126A (en) The use of muramylpeptide compounds
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
DK0994703T3 (da) Sammensætning omfattende ketanserin og L-carnitin til behandlingen af CRPS
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF
DK1463541T3 (da) Biomaterialer baseret på hyaluronsyrebenzylester til anti-angiogen terapi i behandling af tumorer
UA8280A (uk) Спосіб лікування псоріазу
UA22007A (uk) Спосіб лікуваhhя хроhічhого hеспецифічhого простатиту